As of Friday, December 12, Lantheus Holdings, Inc.’s LNTH share price has surged by 5.44%, which has investors questioning if this is right time to sell.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of ...

Shares of gene-editing company Intellia Therapeutics continue to struggle under significant pressure. This follows the U.S. Food and Drug Administration's (FDA) decision to halt the firm's most ...

From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a ...

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Traders should base analysis on the underlying index (XBI), as LABU's price action is distorted by leverage-induced drift.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

Cencora agrees to buy a majority stake in OneOncology for about $5 billion, pauses buybacks, and reiterates fiscal 2026 sales ...